




已阅读5页,还剩30页未读, 继续免费阅读
版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
Therapy of Malignant Pheochromocytoma 恶性嗜铬细胞瘤的治疗,Literature Report,2019/4/25,2,Introduction,rule of 10s for pheochromocytoma (PCC) 10% bilateral 10% extra-adrenal 10% extra-abdomen 10% malignant 10% familial 10% children 10% normal blood pressure,2019/4/25,3,Introduction,The most frequent site of metastases is the skeleton Additional sites are liver, retroperitoneum with lymph nodes, CNS, pleura, and kidney,2019/4/25,4,Malignant vs. Benign,Currently, there is no effective cure for malignant pheochromocytoma. There are also no reliable histopathological methods for distinguishing benign from malignant tumors. Malignancy requires evidence of metastases at non-chromaffin sites distant from that of the primary tumor.,2019/4/25,5,Metastatic disease in pheochromocytoma may be present at the time of initial diagnosis or may only became evident after surgical removal of the primary tumor, usually within 5 years, but sometimes 16 or more years later.,2019/4/25,6,Due to the rarity of the tumor, clinical studies about pheochromocytoma suffer from a fragmented nature and usually involve too small a number of cases to reach conclusive results.,2019/4/25,7,Because there is currently no effective cure for malignant pheochromocytoma, most treatment are palliative, but in some cases may reduce tumor burden and prolong survival. Without treatment, the 5-year survival is generally less than 50%. The course, however, can be highly variable with occasional patients living more than 20 years after diagnosis.,2019/4/25,8,Once malignancy is diagnosed, therapy is generally directed at controlling blood pressure, but may also include tumor debulking.,2019/4/25,9,Alternative of Current Therapy,Surgery Radiopharmaceuticals Combined Chemotherapy Arterial Embolization,2019/4/25,10,Alternative of Current Therapy,Surgery Radiopharmaceuticals Combined Chemotherapy Arterial Embolization,2019/4/25,11,Primary surgical resection is the treatment of choice whenever possible Limited disease: curative intention Extended disease: still to be considered in the first place for debulking and as palliative treatment (Mundschenk et al. 1998),2019/4/25,12,Problem,When signs of regional involvement or distant disease are absent, there is currently no reliable preoperative diagnostic test that can differentiate between malignant and benign pheochromocytomas Should pheochromocytoma size influence surgical approach?,2019/4/25,13,A comparison of 90 malignant and 60 benign pheochromocytomas (Wen T. Shen et al.2004) Comparison of tumor size for benign pheochromocytomas and malignant pheochromocytomas with local disease only Size does not reliably predict malignancy in pheochromocytomas with local disease only,2019/4/25,14,2019/4/25,15,Malignant PCCs presenting with only local disease cannot be discriminated from benign PCCs by size alone. When PCCs do not have evidence of invasion or distant metastases and the surgeon acquires an appropriate level of experience, the majority of these tumors can be safely resected laparoscopically.,2019/4/25,16,Laparoscopic adrenalectomy for pheochromocytoma should be converted to open adrenalectomy for difficult dissection, invasion, adhesions, or surgeon inexperience,2019/4/25,17,Surgical approach,Transabdominal approach is necessary minimally invasive procedures retroperitoneal approaches should be abandoned to definitely preserve the tumor capsule and perform total lymphadecectomy (Orchard et al. 1993),2019/4/25,18,Secondary Tumors,No experience with adjuvant pre and postoperative radiation exists Generally are multiple Radical surgical resection is often impossible Other treatment modalities have to be considered,2019/4/25,19,Alternative of Current Therapy,Surgery Radiopharmaceuticals Combined Chemotherapy Arterial Embolization,2019/4/25,20,2019/4/25,21,131I-MIBG is the treatment of choice for all unresectable, MIBG positive tumors 58 cases of malignant PCC treated by 131I-MIBGtherapeutic results and adverse events (ZHU Ruisen et al. 1999),2019/4/25,22,Patients were classified into 3 groups according to their tumor size 20 cm3 (26 cases) In group 1, the mean absorption dose per gram of tumor was above 1 000 cGy. After treatment ,tumors disappeared or shrinked in all patients,2019/4/25,23,In group 2 , the absorption dose was similar to that of group 1, but the mean absorption dose per gram was 717.6 cGy , and tumor mass regression was 36 % ;76 % reduced urinary catecholamine In group 3 , the absorption dose per gram tumor tissue was 277 cGy , and 30 % tumor enlargement , 20 % died ; the remaining 50 % symptomatic improvement without any change in tumor size,2019/4/25,24,131 I-MIBG is of certain therapeutic effectiveness of symptomatic improvement Complete tumor mass disappearance has only been found in small tumors Treatment with 131 I-MIBG should be instituted immediately after surgical resection to eradicate the residual tumor cells and to prevent recurrences Bone marrow suppression is temporary and not dosage related,2019/4/25,25,In 1997, Loh et al. published a review of the worldwide experience involving 116 patients treated with 131I-MIBG for malignant pheochromocytoma. Overall, there was a symptomatic response in 76%, a hormonal response in 45%, and tumor regression in 30%. The activity of 131I-MIBG per single dose was 96300 mCi, and the mean cumulative activity was 490350 mCi. Only five CRs to 131I-MIBG were reported.,2019/4/25,26,Limitations,Not all patients with multiple metastases of malignant pheochromocytomas have sufficient uptake of MIBG to allow MIBG therapy MIBG negative lesions coexist with MIBG postive lesions, requiring combined treatment,2019/4/25,27,As a single agent,131I-MIBG has limited efficacy in treating malignant pheochromocytoma. Its use in combination with other cytotoxic agents, as is currently being studied in patients with neuroblastoma, may result in additional benefit (Sisson et al. 1999),2019/4/25,28,Alternative of Current Therapy,Surgery Radiopharmaceuticals Combined Chemotherapy Arterial Embolization,2019/4/25,29,Only sparse data on chemotherapeutic regimens are available, most of them in reports of few cases The most well-established regimen is CVD (Averbuch et al. 1988) CTX 750mg/m2 d1, VCR 1.4mg/m2 d1, Dacarbazine 600mg/m2 d1,2 Cycle 21 days,2019/4/25,30,The CVD regimen was based on the treatment for advanced neuroblastoma. This regimen has been reported to produce good responses in
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 呼和浩特市人民医院火针技术操作资格认证
- 中国氧化钐项目商业计划书
- 中国酚醛泡沫塑料项目创业投资方案
- 高档住宅小区保洁服务合同6篇
- 2025年抗病毒口服液市场前景分析
- 2025年上海市汽车驾驶员高级理论知识考试试卷带解析标准卷
- 2025年云南省汽车驾驶员高级理论知识考试试卷带解析【考试直接用】
- 2025年钻井工程项目可行性研究报告
- 2025年中国透皮制剂项目商业计划书
- 中国重质液体石蜡项目创业投资方案
- 2017年上外杯-初赛英语试题
- 《中国政治思想史》课程教学大纲
- 畜牧、兽医科学:家畜环境卫生学题库
- 许继保护装置说明书
- GB/T 2934-2007联运通用平托盘主要尺寸及公差
- GA/T 1476-2018法庭科学远程主机数据获取技术规范
- 《矩阵论》研究生教学课件
- 操作系统第一章答案
- 民用爆炸物品报废及销毁制度(附表单)
- 五大手册-MSA测量系统分析课件
- 小学反邪教工作方案及材料
评论
0/150
提交评论